APA

Huck J. J., Zhang M., Mettetal J., Chakravarty A., Venkatakrishnan K., Zhou X., Kleinfield R., Hyer M. L., Kannan K., Shinde V., Dorner A., Manfredi M. G., Shyu W. C. & Ecsedy J. A. (20151117). Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib). : Molecular cancer therapeutics.

Chicago

Huck Jessica J, Zhang Mengkun, Mettetal Jerome, Chakravarty Arijit, Venkatakrishnan Karthik, Zhou Xiaofei, Kleinfield Rob, Hyer Marc L, Kannan Karuppiah, Shinde Vaishali, Dorner Andy, Manfredi Mark G, Shyu Wen Chyi and Ecsedy Jeffrey A. 20151117. Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib). : Molecular cancer therapeutics.

Harvard

Huck J. J., Zhang M., Mettetal J., Chakravarty A., Venkatakrishnan K., Zhou X., Kleinfield R., Hyer M. L., Kannan K., Shinde V., Dorner A., Manfredi M. G., Shyu W. C. and Ecsedy J. A. (20151117). Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib). : Molecular cancer therapeutics.

MLA

Huck Jessica J, Zhang Mengkun, Mettetal Jerome, Chakravarty Arijit, Venkatakrishnan Karthik, Zhou Xiaofei, Kleinfield Rob, Hyer Marc L, Kannan Karuppiah, Shinde Vaishali, Dorner Andy, Manfredi Mark G, Shyu Wen Chyi and Ecsedy Jeffrey A. Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib). : Molecular cancer therapeutics. 20151117.